{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:03:21Z","timestamp":1789506201957,"version":"build-2803163510"},"reference-count":272,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["F22-00589"],"award-info":[{"award-number":["F22-00589"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Government | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["195886"],"award-info":[{"award-number":["195886"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["PC230507"],"award-info":[{"award-number":["PC230507"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Significant advances in prostate cancer (PCa) treatment have occurred through the integration of molecular biomarkers and imaging with targeted therapies. While androgen receptor pathway inhibition (ARPI) remains the cornerstone of PCa therapy, the current therapeutic landscape has expanded to include a broader range of targeted agents, alongside emerging approaches that leverage disease-specific vulnerabilities. Molecular profiling has enabled the exploration of diverse therapeutic modalities, including epigenetic regulators, immune-modulating agents, metabolic pathways, kinases, and cell surface proteins. Despite this progress, further research is needed to address tumour heterogeneity and treatment-resistant phenotypes. As ARPI use moves earlier in the disease course and novel agents are incorporated into standard care, prolonging disease control may also reshape emergent resistant phenotypes and disease progression trajectories. This evolving context underscores the need to revisit agents that may now show efficacy in new therapeutic settings or when paired with complementary strategies. Here, we review the current treatment framework in PCa and highlight novel approaches and targets poised to transform clinical care.<\/jats:p>","DOI":"10.1038\/s44321-025-00282-8","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T16:48:49Z","timestamp":1754326129000},"page":"2191-2214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["New frontiers in prostate cancer treatment from systemic therapy to targeted therapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Shaghayegh","family":"Nouruzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Kobelev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakisa","family":"Tabrizian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4235-0167","authenticated-orcid":false,"given":"Martin","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0498-142X","authenticated-orcid":false,"given":"Amina","family":"Zoubeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"282_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","volume":"84","author":"W Abida","year":"2023","unstructured":"Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, Zhang J, Burke JM, Castellano D, Font A et al (2023) Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. Eur Urol 84:321\u2013330","journal-title":"Eur Urol"},{"key":"282_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF et al (2019a) Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 5:471\u2013478","journal-title":"JAMA Oncol"},{"key":"282_CR4","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM et al (2019b) Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 116:11428\u201311436","journal-title":"Proc Natl Acad Sci USA"},{"key":"282_CR269","doi-asserted-by":"crossref","unstructured":"Achard V, Tombal B (2024) High-risk biochemical recurrence of locally treated prostate cancer after EMBARK. An end to decades of conventional wisdom? Prostate Cancer Prostatic Dis 27:665\u2013666","DOI":"10.1038\/s41391-023-00767-y"},{"key":"282_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC et al (2023) Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402:291\u2013303","journal-title":"Lancet"},{"key":"282_CR6","doi-asserted-by":"publisher","first-page":"113249","DOI":"10.1016\/j.ejca.2023.113249","volume":"192","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Zhang T, Efstathiou E, Sayegh N, Engelsberg A, Saad F, Fizazi K (2023) The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur J Cancer 192:113249","journal-title":"Eur J Cancer"},{"key":"282_CR7","doi-asserted-by":"publisher","first-page":"e162148","DOI":"10.1172\/JCI162148","volume":"133","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Fang L, McGowen K, Yin J, Bowman J, Ku AT, Alilin AN, Corey E, Roudier MP, True LD et al (2023) Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. J Clin Invest 133:e162148","journal-title":"J Clin Invest"},{"key":"282_CR8","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON et al (2018) Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 36:2492\u20132503","journal-title":"J Clin Oncol"},{"key":"282_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00599-6","volume":"8","author":"A Ajkunic","year":"2024","unstructured":"Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, Hanratty B, Adil M, Zhao J, Zaidi S et al (2024) Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. NPJ Precis Oncol 8:104","journal-title":"NPJ Precis Oncol"},{"key":"282_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/iju.13526","volume":"25","author":"S Akamatsu","year":"2018","unstructured":"Akamatsu S, Inoue T, Ogawa O, Gleave ME (2018) Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int J Urol 25:345\u2013351","journal-title":"Int J Urol"},{"key":"282_CR11","doi-asserted-by":"publisher","first-page":"108255","DOI":"10.1016\/j.pharmthera.2022.108255","volume":"238","author":"BR Alabi","year":"2022","unstructured":"Alabi BR, Liu S, Stoyanova T (2022) Current and emerging therapies for neuroendocrine prostate cancer. Pharm Ther 238:108255","journal-title":"Pharm Ther"},{"key":"282_CR12","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383:2207\u20132218","journal-title":"N Engl J Med"},{"key":"282_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","volume":"8","author":"M Annala","year":"2018","unstructured":"Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D (2018) Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov 8:444\u2013457","journal-title":"Cancer Discov"},{"key":"282_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1200\/PO.19.00399","volume":"4","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M (2020) CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis Oncol 4:370\u2013381","journal-title":"JCO Precis Oncol"},{"key":"282_CR15","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A (2022) Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 40:1616\u20131622","journal-title":"J Clin Oncol"},{"key":"282_CR271","doi-asserted-by":"crossref","unstructured":"Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510:278\u2013282","DOI":"10.1038\/nature13229"},{"key":"282_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1200\/JCO.2022.40.6_suppl.093","volume":"40","author":"MO Atiq","year":"2022","unstructured":"Atiq MO, Chandran EBA, Meininger L, Karzai F, Bilusic M, Marte JL, Arlen PM, Cordes LM, Strauss J, Redman J, Floudas CS, Pastor DM, Owens H, Hankin A, Williams M, Figg WD, Dahut WL, Schlom J, Gulley JL, Madan RA (2022) Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer. J Clin Oncol 40:93\u201393","journal-title":"J Clin Oncol"},{"key":"282_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","volume":"35","author":"MA Augello","year":"2019","unstructured":"Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y, Rubin MA, Beltran H, Elemento O, Bergman AM, Zwart W, Sboner A, Dephoure N, Barbieri CE (2019) CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis. Cancer Cell 35:603\u2013617.e8","journal-title":"Cancer Cell"},{"key":"282_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1158\/1535-7163.MCT-20-0061","volume":"20","author":"RJ Austin","year":"2021","unstructured":"Austin RJ, Lemon BD, Aaron WH, Barath M, Culp PA, DuBridge RB, Evnin LB, Jones A, Panchal A, Patnaik P et al (2021) TriTACs, a novel class of T-cell-engaging protein constructs designed for the treatment of solid tumors. Mol Cancer Ther 20:109\u2013120","journal-title":"Mol Cancer Ther"},{"key":"282_CR19","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","volume":"29","author":"SC Baca","year":"2023","unstructured":"Baca SC, Seo JH, Davidsohn MP, Fortunato B, Semaan K, Sotudian S, Lakshminarayanan G, Diossy M, Qiu X, El Zarif T et al (2023) Liquid biopsy epigenomic profiling for cancer subtyping. Nat Med 29:2737\u20132741","journal-title":"Nat Med"},{"key":"282_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22139-7","volume":"12","author":"SC Baca","year":"2021","unstructured":"Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O\u2019Connor E et al (2021) Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun 12:1979","journal-title":"Nat Commun"},{"key":"282_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41585-020-0288-x","volume":"17","author":"DA Bader","year":"2020","unstructured":"Bader DA, McGuire SE (2020) Tumour metabolism and its unique properties in prostate adenocarcinoma. Nat Rev Urol 17:214\u2013231","journal-title":"Nat Rev Urol"},{"key":"282_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.eururo.2013.05.029","volume":"64","author":"CE Barbieri","year":"2013","unstructured":"Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, Luo J, Visakorpi T, Rubin MA (2013) The mutational landscape of prostate cancer. Eur Urol 64:567\u2013576","journal-title":"Eur Urol"},{"key":"282_CR23","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00432-022-04371-w","volume":"149","author":"AK Beier","year":"2023","unstructured":"Beier AK, Puhr M, Stope MB, Thomas C, Erb HHH (2023) Metabolic changes during prostate cancer development and progression. J Cancer Res Clin Oncol 149:2259\u20132270","journal-title":"J Cancer Res Clin Oncol"},{"key":"282_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ymgme.2005.12.014","volume":"88","author":"I Bellezza","year":"2006","unstructured":"Bellezza I, Bracarda S, Caserta C, Minelli A (2006) Targeting of EGFR tyrosine kinase by ZD1839 (\u201cIressa\u201d) in androgen-responsive prostate cancer in vitro. Mol Genet Metab 88:114\u2013122","journal-title":"Mol Genet Metab"},{"key":"282_CR25","doi-asserted-by":"publisher","first-page":"T67","DOI":"10.1530\/ERC-21-0140","volume":"28","author":"H Beltran","year":"2021","unstructured":"Beltran H, Demichelis F (2021) Therapy considerations in neuroendocrine prostate cancer: what next?. Endocr Relat Cancer 28:T67\u2013T78","journal-title":"Endocr Relat Cancer"},{"key":"282_CR26","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J et al (2019) The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res 25:6916\u20136924","journal-title":"Clin Cancer Res"},{"key":"282_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298\u2013305","journal-title":"Nat Med"},{"key":"282_CR28","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1172\/JCI131041","volume":"130","author":"H Beltran","year":"2020","unstructured":"Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GM, Orlando F, Fedrizzi T, Ku SY, Dann E, Alonso A, Mosquera JM, Sboner A, Xiang J, Elemento O, Nanus DM, Tagawa ST, Benelli M, Demichelis F (2020) Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest 130:1653\u20131668","journal-title":"J Clin Invest"},{"key":"282_CR29","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1172\/JCI127961","volume":"129","author":"A Berger","year":"2019","unstructured":"Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, Hwang I, Bagadion AM, Sboner A, Elemento O, Paik J, Yu J, Barbieri CE, Dephoure N, Beltran H, Rickman DS (2019) N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest 129:3924\u20133940","journal-title":"J Clin Invest"},{"key":"282_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37874-2","volume":"14","author":"V Bhatia","year":"2023","unstructured":"Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I et al (2023) Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun 14:2041","journal-title":"Nat Commun"},{"key":"282_CR31","doi-asserted-by":"publisher","first-page":"e2305724","DOI":"10.1002\/advs.202305724","volume":"11","author":"X Bian","year":"2024","unstructured":"Bian X, Wang W, Abudurexiti M, Zhang X, Ma W, Shi G, Du L, Xu M, Wang X, Tan C, Sun H, He X, Zhang C, Zhu Y, Zhang M, Ye D, Wang J (2024) Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity. Adv Sci 11:e2305724","journal-title":"Adv Sci"},{"key":"282_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/cr.2009.43","volume":"19","author":"I Bisson","year":"2009","unstructured":"Bisson I, Prowse DM (2009) WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19:683\u2013697","journal-title":"Cell Res"},{"key":"282_CR33","doi-asserted-by":"publisher","first-page":"101970","DOI":"10.1016\/j.isci.2020.101970","volume":"24","author":"T Bland","year":"2021","unstructured":"Bland T, Wang J, Yin L, Pu T, Li J, Gao J, Lin TP, Gao AC, Wu BJ (2021) WLS-Wnt signaling promotes neuroendocrine prostate cancer. iScience 24:101970","journal-title":"iScience"},{"key":"282_CR34","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1101\/gad.16962311","volume":"25","author":"D Blazek","year":"2011","unstructured":"Blazek D, Kohoutek J, Bartholomeeusen K, Johansen E, Hulinkova P, Luo Z, Cimermancic P, Ule J, Peterlin BM (2011) The Cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 25:2158\u20132172","journal-title":"Genes Dev"},{"key":"282_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/030089169207800215","volume":"78","author":"F Boccardo","year":"1992","unstructured":"Boccardo F, Guarneri D, Pace M, Decensi A, Oneto F, Martorana G (1992) Phase II study with lonidamine in the treatment of hormone-refractory prostatic cancer patients. Tumori 78:137\u2013139","journal-title":"Tumori"},{"key":"282_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07058-y","volume":"20","author":"MJ Bou-Dargham","year":"2020","unstructured":"Bou-Dargham MJ, Sha L, Sang QA, Zhang J (2020) Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy. BMC Cancer 20:572","journal-title":"BMC Cancer"},{"key":"282_CR37","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-18-0937","volume":"24","author":"G Boysen","year":"2018","unstructured":"Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D et al (2018) SPOP-mutated\/CHD1-deleted lethal prostate cancer and abiraterone sensitivity. Clin Cancer Res 24:5585\u20135593","journal-title":"Clin Cancer Res"},{"key":"282_CR38","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/jnci\/djt174","volume":"105","author":"TM Brasky","year":"2013","unstructured":"Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR (2013) Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 105:1132\u20131141","journal-title":"J Natl Cancer Inst"},{"key":"282_CR39","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41391-022-00524-7","volume":"25","author":"LC Brown","year":"2022","unstructured":"Brown LC, Halabi S, Somarelli JA, Humeniuk M, Wu Y, Oyekunle T, Howard L, Huang J, Anand M, Davies C, Patel P, Staats J, Weinhold KJ, Harrison MR, Zhang T, George DJ, Armstrong AJ (2022) A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis 25:762\u2013769","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"282_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1200\/JCO.2005.02.129","volume":"23","author":"CM Canil","year":"2005","unstructured":"Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L (2005) Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23:455\u2013460","journal-title":"J Clin Oncol"},{"key":"282_CR41","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.18632\/oncotarget.1802","volume":"5","author":"B Cao","year":"2014","unstructured":"Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y (2014) Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5:1646\u20131656","journal-title":"Oncotarget"},{"key":"282_CR42","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","volume":"11","author":"S Carreira","year":"2021","unstructured":"Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C et al (2021) Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial. Cancer Discov 11:2812\u20132827","journal-title":"Cancer Discov"},{"key":"282_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36253-1","volume":"14","author":"G Chakraborty","year":"2023","unstructured":"Chakraborty G, Gupta K, Kyprianou N (2023) Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer. Nat Commun 14:567","journal-title":"Nat Commun"},{"key":"282_CR44","doi-asserted-by":"publisher","first-page":"563.e1","DOI":"10.1016\/j.clgc.2021.07.014","volume":"19","author":"J Cham","year":"2021","unstructured":"Cham J, Venkateswaran AR, Bhangoo M (2021) Targeting the PI3K-AKT-mTOR pathway in castration resistant prostate cancer: a review article. Clin Genitourin Cancer 19:563.e1\u2013563.e7","journal-title":"Clin Genitourin Cancer"},{"key":"282_CR45","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1126\/science.abn0478","volume":"377","author":"JM Chan","year":"2022","unstructured":"Chan JM, Zaidi S, Love JR, Zhao JL, Setty M, Wadosky KM, Gopalan A, Choo ZN, Persad S, Choi J et al (2022) Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science 377:1180\u20131191","journal-title":"Science"},{"key":"282_CR46","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","volume":"154","author":"KH Chang","year":"2013","unstructured":"Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, Mirzaei H, Auchus RJ, Sharifi N (2013) A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154:1074\u20131084","journal-title":"Cell"},{"key":"282_CR47","doi-asserted-by":"publisher","first-page":"101752","DOI":"10.1016\/j.xcrm.2024.101752","volume":"5","author":"Y Chang","year":"2024","unstructured":"Chang Y, Wang X, Yang J, Tien JC, Mannan R, Cruz G, Zhang Y, Vo JN, Magnuson B, Mahapatra S et al (2024) Development of an orally bioavailable CDK12\/13 degrader and induction of synthetic lethality with AKT pathway inhibition. Cell Rep Med 5:101752","journal-title":"Cell Rep Med"},{"key":"282_CR48","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1172\/JCI127613","volume":"129","author":"P Chatterjee","year":"2019","unstructured":"Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS (2019) Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. J Clin Invest 129:4245\u20134260","journal-title":"J Clin Invest"},{"key":"282_CR49","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17:3520\u20133526","journal-title":"Clin Cancer Res"},{"key":"282_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/aja202363","volume":"26","author":"L Chen","year":"2024","unstructured":"Chen L, Xu YX, Wang YS, Zhou JL (2024) Lipid metabolism, amino acid metabolism, and prostate cancer: a crucial metabolic journey. Asian J Androl 26:123\u2013134","journal-title":"Asian J Androl"},{"key":"282_CR51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.4103\/tcmj.tcmj_220_20","volume":"33","author":"WC Cheng","year":"2021","unstructured":"Cheng WC, Wang HJ (2021) Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer. Tzu Chi Med J 33:224\u2013232","journal-title":"Tzu Chi Med J"},{"key":"282_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Gomes AJPDS, Given R, Soto \u00c1J, Merseburger AS, \u00d6zg\u00fcro\u011flu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S (2019) Apalutamide for Metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13\u201324","journal-title":"N Engl J Med"},{"key":"282_CR53","doi-asserted-by":"crossref","unstructured":"Chi KN, Rathkopf DE, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Gomes AJ, Roubaud G (2022) Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Am Soc Clin Oncol 34(9):772-782","DOI":"10.1016\/j.annonc.2023.10.087"},{"key":"282_CR54","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/2326-6066.CIR-19-0518","volume":"8","author":"D Chiu","year":"2020","unstructured":"Chiu D, Tavare R, Haber L, Aina OH, Vazzana K, Ram P, Danton M, Finney J, Jalal S, Krueger P, Giurleo JT, Ma D, Smith E, Thurston G, Kirshner JR, Crawford A (2020) A PSMA-targeting CD3 bispecific antibody induces antitumor responses that are enhanced by 4-1BB costimulation. Cancer Immunol Res 8:596\u2013608","journal-title":"Cancer Immunol Res"},{"key":"282_CR55","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1158\/1078-0432.CCR-15-1624","volume":"22","author":"SY Choi","year":"2016","unstructured":"Choi SY, Xue H, Wu R, Fazli L, Lin D, Collins CC, Gleave ME, Gout PW, Wang Y (2016) The MCT4 gene: a novel, potential target for therapy of advanced prostate cancer. Clin Cancer Res 22:2721\u20132733","journal-title":"Clin Cancer Res"},{"key":"282_CR56","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1002\/cam4.1587","volume":"7","author":"SYC Choi","year":"2018","unstructured":"Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner NE, Gleave ME, Collins CC, Wang Y (2018) Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Med 7:3385\u20133392","journal-title":"Cancer Med"},{"key":"282_CR57","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-23-3785","volume":"30","author":"J Chou","year":"2024","unstructured":"Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, Mikayelyan M, Delavan H, Swinderman J, Wilson C et al (2024) Synthetic lethal targeting of cyclin dependent kinase-12-deficient prostate cancer with PARP inhibitors. Clin Cancer Res 30:5445\u20135458","journal-title":"Clin Cancer Res"},{"key":"282_CR58","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, Procopio G, de Menezes J, Girotto G, Arslan C (2022) Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 1:EVIDoa2200043","journal-title":"NEJM Evid"},{"key":"282_CR59","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.neo.2020.04.002","volume":"22","author":"DJ Coleman","year":"2020","unstructured":"Coleman DJ, Sampson DA, Sehrawat A, Kumaraswamy A, Sun D, Wang Y, Schwartzman J, Urrutia J, Lee AR, Coleman IM, Nelson PS, Dong X, Morrissey C, Corey E, Xia Z, Yates JA, Alumkal JJ (2020) Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. Neoplasia 22:253\u2013262","journal-title":"Neoplasia"},{"key":"282_CR60","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11033-015-3858-x","volume":"42","author":"R Courtnay","year":"2015","unstructured":"Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC (2015) Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep 42:841\u2013851","journal-title":"Mol Biol Rep"},{"key":"282_CR61","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.20.01576","volume":"39","author":"SJ Crabb","year":"2021","unstructured":"Crabb SJ, Griffiths G, Marwood E, Dunkley D, Downs N, Martin K, Light M, Northey J, Wilding S, Whitehead A (2021) Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID). J Clin Oncol 39:190","journal-title":"J Clin Oncol"},{"key":"282_CR62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L (2019) Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 22:24\u201338","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"282_CR63","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","volume":"367","author":"JM Crook","year":"2012","unstructured":"Crook JM, O\u2019Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A et al (2012) Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895\u2013903","journal-title":"N Engl J Med"},{"key":"282_CR64","doi-asserted-by":"publisher","first-page":"113221","DOI":"10.1016\/j.celrep.2023.113221","volume":"42","author":"PD Crowell","year":"2023","unstructured":"Crowell PD, Giafaglione JM, Jones AE, Nunley NM, Hashimoto T, Delcourt AML, Petcherski A, Agrawal R, Bernard MJ, Diaz JA et al (2023) MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Rep 42:113221","journal-title":"Cell Rep"},{"key":"282_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19328-1","volume":"11","author":"J Cyrta","year":"2020","unstructured":"Cyrta J, Augspach A, De Filippo MR, Prandi D, Thienger P, Benelli M, Cooley V, Bareja R, Wilkes D, Chae SS et al (2020) Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity. Nat Commun 11:5549","journal-title":"Nat Commun"},{"key":"282_CR66","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.19.00646","volume":"37","author":"DC Danila","year":"2019","unstructured":"Danila DC, Szmulewitz RZ, Vaishampayan U, Higano CS, Baron AD, Gilbert HN, Brunstein F, Milojic-Blair M, Wang B, Kabbarah O, Mamounas M, Fine BM, Maslyar DJ, Ungewickell A, Scher HI (2019) Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer. J Clin Oncol 37:3518\u20133527","journal-title":"J Clin Oncol"},{"key":"282_CR67","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al (2016) N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30:563\u2013577","journal-title":"Cancer Cell"},{"key":"282_CR68","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1021\/acsptsci.3c00159","volume":"6","author":"G Das","year":"2023","unstructured":"Das G, Ptacek J, Havlinova B, Nedvedova J, Barinka C, Novakova Z (2023) Targeting prostate cancer using bispecific T-cell engagers against prostate-specific membrane antigen. ACS Pharm Transl Sci 6:1703\u20131714","journal-title":"ACS Pharm Transl Sci"},{"key":"282_CR69","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoglanoglu F, Omur ME, Kim S, Kobelev M et al (2021a) An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol 23:1023\u20131034","journal-title":"Nat Cell Biol"},{"key":"282_CR70","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karao\u011flano\u011flu F, Omur ME, Kim S, Kobelev M et al (2021b) An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol 23:1023\u20131034","journal-title":"Nat Cell Biol"},{"key":"282_CR71","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1158\/2159-8290.CD-23-0225","volume":"13","author":"A Davies","year":"2023","unstructured":"Davies A, Zoubeidi A, Beltran H, Selth LA (2023) The transcriptional and epigenetic landscape of cancer cell lineage plasticity. Cancer Discov 13:1771\u20131788","journal-title":"Cancer Discov"},{"key":"282_CR72","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1530\/ERC-19-0420","volume":"27","author":"A Davies","year":"2020","unstructured":"Davies A, Zoubeidi A, Selth LA (2020) The epigenetic and transcriptional landscape of neuroendocrine prostate cancer. Endocr Relat Cancer 27:R35\u2013R50","journal-title":"Endocr Relat Cancer"},{"key":"282_CR73","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091\u20132102","journal-title":"N Engl J Med"},{"key":"282_CR74","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","volume":"87","author":"JS de Bono","year":"2025","unstructured":"de Bono JS, He M, Shi Z, Nowicka M, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, Matsubara N, Chen G, Bienz NS, Canter D, Wongchenko M, Sweeney C (2025) Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial. Eur Urol 87:672\u2013682","journal-title":"Eur Urol"},{"key":"282_CR75","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1158\/1078-0432.CCR-21-4302","volume":"28","author":"I de Kouchkovsky","year":"2022","unstructured":"de Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, Small EJ, Friedlander T, Fong L, Paris PL, Ryan CJ, Szmulewitz RZ, Aggarwal R (2022) A phase Ib\/II study of the CDK4\/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer. Clin Cancer Res 28:1531\u20131539","journal-title":"Clin Cancer Res"},{"key":"282_CR76","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2159-8290.CD-22-0692","volume":"13","author":"N De Sarkar","year":"2023","unstructured":"De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP et al (2023) Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes. Cancer Discov 13:632\u2013653","journal-title":"Cancer Discov"},{"key":"282_CR77","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41388-021-02157-x","volume":"41","author":"L de Wet","year":"2022","unstructured":"de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, Wang H, Platz EA, De Marzo AM, Mu P, Coloff JL, Szmulewitz RZ, Vander Griend DJ (2022) SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene 41:1190\u20131202","journal-title":"Oncogene"},{"key":"282_CR78","doi-asserted-by":"publisher","first-page":"8471","DOI":"10.1128\/MCB.21.24.8471-8482.2001","volume":"21","author":"PD Deeble","year":"2001","unstructured":"Deeble PD, Murphy DJ, Parsons SJ, Cox ME (2001) Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21:8471\u20138482","journal-title":"Mol Cell Biol"},{"key":"282_CR79","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","volume":"27","author":"P Deegen","year":"2021","unstructured":"Deegen P, Thomas O, Nolan-Stevaux O, Li S, Wahl J, Bogner P, Aeffner F, Friedrich M, Liao MZ, Matthes K, Rau D, Rattel B, Raum T, Kufer P, Coxon A, Bailis JM (2021) The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer. Clin Cancer Res 27:2928\u20132937","journal-title":"Clin Cancer Res"},{"key":"282_CR80","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:904\u2013917","journal-title":"Cell"},{"key":"282_CR81","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/1078-0432.CCR-20-3396","volume":"27","author":"DC DeLucia","year":"2021","unstructured":"DeLucia DC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, da Costa RMG, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK (2021) Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. Clin Cancer Res 27:759\u2013774","journal-title":"Clin Cancer Res"},{"key":"282_CR82","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","volume":"3","author":"S Deng","year":"2022","unstructured":"Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, Mukherji A, Lo UG, Xu L, Gonzalez J et al (2022) Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat Cancer 3:1071\u20131087","journal-title":"Nat Cancer"},{"key":"282_CR83","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J (2021) Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol 18:773\u2013791","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 7","key":"282_CR84","first-page":"S27","volume":"7","author":"P Ditonno","year":"2005","unstructured":"Ditonno P, Battaglia M, Selvaggio O, Garofalo L, Lorusso V, Selvaggi FP (2005) Clinical evidence supporting the role of lonidamine for the treatment of BPH. Rev Urol 7(Suppl 7):S27\u2013S33","journal-title":"Rev Urol"},{"key":"282_CR85","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","volume":"35","author":"E Dotan","year":"2017","unstructured":"Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD (2017) Phase I\/II trial of labetuzumab govitecan (anti-CEACAM5\/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol 35:3338\u20133346","journal-title":"J Clin Oncol"},{"key":"282_CR86","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W (2020) EZH2: a novel target for cancer treatment. J Hematol Oncol 13:104","journal-title":"J Hematol Oncol"},{"key":"282_CR87","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/cancers16162871","volume":"16","author":"HHH Erb","year":"2024","unstructured":"Erb HHH, Polishchuk N, Stasyk O, Kahya U, Weigel MM, Dubrovska A (2024) Glutamine metabolism and prostate cancer. Cancers 16:2871","journal-title":"Cancers"},{"key":"282_CR88","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/1541-7786.MCR-16-0221","volume":"15","author":"EJ Faivre","year":"2017","unstructured":"Faivre EJ, Wilcox D, Lin X, Hessler P, Torrent M, He W, Uziel T, Albert DH, McDaniel K, Kati W, Shen Y (2017) Exploitation of castration-resistant prostate cancer transcription factor dependencies by the novel BET inhibitor ABBV-075. Mol Cancer Res 15:35\u201344","journal-title":"Mol Cancer Res"},{"key":"282_CR89","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1535-7163.MCT-21-0581","volume":"21","author":"E Farah","year":"2022","unstructured":"Farah E, Zhang Z, Utturkar SM, Liu J, Ratliff TL, Liu X (2022) Targeting DNMTs to overcome enzalutamide resistance in prostate cancer. Mol Cancer Ther 21:193\u2013205","journal-title":"Mol Cancer Ther"},{"key":"282_CR90","first-page":"241620","volume":"65","author":"Y Feng","year":"2024","unstructured":"Feng Y, Hu W, Gai Y, Lin Z, Zhang X, Wang X, Zhang Y, An R, Shi Y, Lan X (2024) TROP2-targeted immunoSPECT imaging in prostate cancer utilizing humanized VHH-Fc for precision diagnosis. J Nucl Med 65:241620","journal-title":"J Nucl Med"},{"key":"282_CR91","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21873\/cgp.20319","volume":"19","author":"O Fiala","year":"2022","unstructured":"Fiala O, Baxa J, Svaton M, Benesova L, Ptackova R, Halkova T, Minarik M, Hosek P, Buresova M, Finek J, Ferda J, Pesek M (2022) Combination of circulating tumour DNA and (18)F-FDG PET\/CT for precision monitoring of therapy response in patients with advanced non-small cell lung cancer: a prospective study. Cancer Genomics Proteom 19:270\u2013281","journal-title":"Cancer Genomics Proteom"},{"key":"282_CR92","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrd4286","volume":"13","author":"P Filippakopoulos","year":"2014","unstructured":"Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13:337\u2013356","journal-title":"Nat Rev Drug Discov"},{"key":"282_CR93","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2217\/epi-2023-0374","volume":"16","author":"I Fischetti","year":"2024","unstructured":"Fischetti I, Botti L, Sulsenti R, Cancila V, Enriquez C, Ferri R, Bregni M, Crivelli F, Tripodo C, Colombo MP, Jachetti E (2024) Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response. Epigenomics 16:653\u2013670","journal-title":"Epigenomics"},{"key":"282_CR94","first-page":"EVIDoa2300171","volume":"3","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Bernard-Tessier A, Roubaud G, Utriainen T, Barthelemy P, Flechon A, van der Voet J, Gravis G, Ratta R, Jones R, Parikh O, Tanner M, Antonarakis ES, Baldini C, Peters N, Garratt C, Ikonen T, Pohjanjousi P, Joensuu H, Cook N (2024) Targeted inhibition of CYP11A1 in castration-resistant prostate cancer. NEJM Evid 3:EVIDoa2300171","journal-title":"NEJM Evid"},{"key":"282_CR95","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U (2023) Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med 388:719\u2013732","journal-title":"N Engl J Med"},{"key":"282_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, Kollmannsberger C, Kwan EM, Parekh K, Schonlau E et al (2024) Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun 15:1828","journal-title":"Nat Commun"},{"key":"282_CR97","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s00262-023-03459-7","volume":"72","author":"SE Franks","year":"2023","unstructured":"Franks SE, Santiago-Sanchez GS, Fabian KP, Solocinski K, Chariou PL, Hamilton DH, Kowalczyk JT, Padget MR, Gameiro SR, Schlom J, Hodge JW (2023) Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12. Cancer Immunol Immunother 72:2783\u20132797","journal-title":"Cancer Immunol Immunother"},{"key":"282_CR98","doi-asserted-by":"publisher","first-page":"e046588","DOI":"10.1136\/bmjopen-2020-046588","volume":"11","author":"SJ Freedland","year":"2021","unstructured":"Freedland SJ, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J, Haas GP, Shore ND (2021) A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open 11:e046588","journal-title":"BMJ Open"},{"key":"282_CR99","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5534\/wjmh.180040","volume":"37","author":"K Fujita","year":"2019","unstructured":"Fujita K, Nonomura N (2019) Role of androgen receptor in prostate cancer: a review. World J Mens Health 37:288\u2013295","journal-title":"World J Mens Health"},{"key":"282_CR100","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","volume":"31","author":"R Ge","year":"2020","unstructured":"Ge R, Wang Z, Montironi R, Jiang Z, Cheng M, Santoni M, Huang K, Massari F, Lu X, Cimadamore A, Lopez-Beltran A, Cheng L (2020) Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann Oncol 31:470\u2013479","journal-title":"Ann Oncol"},{"key":"282_CR101","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1038\/sj.onc.1205142","volume":"21","author":"S Gery","year":"2002","unstructured":"Gery S, Sawyers CL, Agus DB, Said JW, Koeffler HP (2002) TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 21:4739\u20134746","journal-title":"Oncogene"},{"key":"282_CR102","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algul H, O\u2019Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317\u2013327","journal-title":"N Engl J Med"},{"key":"282_CR103","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S et al (2017) Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov 7:1006\u20131017","journal-title":"Cancer Discov"},{"key":"282_CR104","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/humu.22046","volume":"33","author":"B Gottlieb","year":"2012","unstructured":"Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M (2012) The androgen receptor gene mutations database: 2012 update. Hum Mutat 33:887\u2013894","journal-title":"Hum Mutat"},{"key":"282_CR105","doi-asserted-by":"publisher","first-page":"e225394","DOI":"10.1001\/jamanetworkopen.2022.5394","volume":"5","author":"RP Graf","year":"2022","unstructured":"Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, Sayegh N, Lin DI, Raskina K, Schrock AB, Severson E, Haberberger JF, Ross JS, Creeden J, Levy MA, Alexander BM, Oxnard GR, Agarwal N (2022) Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer. JAMA Netw Open 5:e225394","journal-title":"JAMA Netw Open"},{"key":"282_CR106","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3892\/or.2012.2192","volume":"29","author":"GL Gravina","year":"2013","unstructured":"Gravina GL, Ranieri G, Muzi P, Marampon F, Mancini A, Di Pasquale B, Di Clemente L, Dolo V, D\u2019Alessandro AM, Festuccia C (2013) Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. Oncol Rep 29:1189\u20131195","journal-title":"Oncol Rep"},{"key":"282_CR107","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mce.2011.09.046","volume":"360","author":"SM Green","year":"2012","unstructured":"Green SM, Mostaghel EA, Nelson PS (2012) Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 360:3\u201313","journal-title":"Mol Cell Endocrinol"},{"key":"282_CR108","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","volume":"59","author":"N Gulati","year":"2018","unstructured":"Gulati N, Beguelin W, Giulino-Roth L (2018) Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma 59:1574\u20131585","journal-title":"Leuk Lymphoma"},{"key":"282_CR109","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J et al (2023) B7-H3 as a therapeutic target in advanced prostate cancer. Eur Urol 83:224\u2013238","journal-title":"Eur Urol"},{"key":"282_CR110","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","volume":"69","author":"Z Guo","year":"2009","unstructured":"Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69:2305\u20132313","journal-title":"Cancer Res"},{"key":"282_CR111","first-page":"PO.17.00140","volume":"1","author":"GC Han","year":"2017","unstructured":"Han GC, Hwang J, Wankowicz SAM, Zhang Z, Liu D, Cibulskis C, Gaviola GC, Ghazikhanian V, McKay RR, Bubley GJ, Carter SL, Balk SP, Hahn WC, Taplin ME, Van Allen EM (2017) Genomic resistance patterns to second-generation androgen blockade in paired tumor biopsies of metastatic castration-resistant prostate cancer. JCO Precis Oncol 1:PO.17.00140","journal-title":"JCO Precis Oncol"},{"key":"282_CR112","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346","journal-title":"Cancer Discov"},{"key":"282_CR113","first-page":"207","volume":"25","author":"K Hannu","year":"2014","unstructured":"Hannu K, Johanna M, Ulf-Hakan S (2014) KLK-targeted therapies for prostate cancer. EJIFCC 25:207\u2013218","journal-title":"EJIFCC"},{"key":"282_CR114","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/jco.2015.33.15_suppl.2512","volume":"33","author":"JJ Harding","year":"2015","unstructured":"Harding JJ, Telli ML, Munster PN, Le MH, Molineaux C, Bennett MK, Mittra E, Burris HA, Clark AS, Dunphy M, Meric-Bernstam F, Patel MR, DeMichele A, Infante JR (2015) Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. J Clin Oncol 33:2512","journal-title":"J Clin Oncol"},{"key":"282_CR115","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of U (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467\u2013479","journal-title":"Eur Urol"},{"key":"282_CR116","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S et al (2021) [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397:797\u2013804","journal-title":"Lancet"},{"key":"282_CR117","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","volume":"30","author":"M Hussain","year":"2024","unstructured":"Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, Picus J, Reichert ZR, Szmulewitz RZ, Tagawa ST et al (2024) Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway). Clin Cancer Res 30:4318\u20134328","journal-title":"Clin Cancer Res"},{"key":"282_CR118","doi-asserted-by":"publisher","first-page":"e2351700","DOI":"10.1001\/jamanetworkopen.2023.51700","volume":"7","author":"WT Iams","year":"2024","unstructured":"Iams WT, Mackay M, Ben-Shachar R, Drews J, Manghnani K, Hockenberry AJ, Cristofanilli M, Nimeiri H, Guinney J, Benson AB 3rd (2024) Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort. JAMA Netw Open 7:e2351700","journal-title":"JAMA Netw Open"},{"key":"282_CR119","doi-asserted-by":"publisher","first-page":"1498391","DOI":"10.3389\/fimmu.2024.1498391","volume":"15","author":"P Jabbarzadeh Kaboli","year":"2024","unstructured":"Jabbarzadeh Kaboli P, Roozitalab G, Farghadani R, Eskandarian Z, Zerrouqi A (2024) c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity. Front Immunol 15:1498391","journal-title":"Front Immunol"},{"key":"282_CR120","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/pros.24707","volume":"84","author":"S Jasmine","year":"2024","unstructured":"Jasmine S, Mandl A, Krueger TEG, Dalrymple SL, Antony L, Dias J, Celatka CA, Tapper AE, Kleppe M, Kanayama M et al (2024) Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models. Prostate 84:909\u2013921","journal-title":"Prostate"},{"key":"282_CR121","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s13402-023-00822-9","volume":"46","author":"Y Ji","year":"2023","unstructured":"Ji Y, Liu B, Chen L, Li A, Shen K, Su R, Zhang W, Zhu Y, Wang Q, Xue W (2023) Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6\/STAT3 pathway. Cell Oncol 46:1445\u20131456","journal-title":"Cell Oncol"},{"key":"282_CR122","first-page":"538","volume":"59","author":"D Jiang","year":"2018","unstructured":"Jiang D, Kang L, Ehlerding E, Ni D, Yu B, Wei W, Engle J, Cai W (2018) ImmunoPET imaging and radioimmunotherapy of prostate cancer with an anti-Trop2 antibody. J Nucl Med 59:538","journal-title":"J Nucl Med"},{"key":"282_CR123","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijrobp.2009.07.1731","volume":"78","author":"G Joensuu","year":"2010","unstructured":"Joensuu G, Joensuu T, Nokisalmi P, Reddy C, Isola J, Ruutu M, Kouri M, Kupelian PA, Collan J, Pesonen S, Hemminki A (2010) A phase I\/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 78:42\u201349","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"282_CR124","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00018-022-04396-x","volume":"79","author":"K Joshi","year":"2022","unstructured":"Joshi K, Liu S, Breslin SJP, Zhang J (2022) Mechanisms that regulate the activities of TET proteins. Cell Mol Life Sci 79:363","journal-title":"Cell Mol Life Sci"},{"key":"282_CR125","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-22-0115","volume":"21","author":"M Karimaa","year":"2022","unstructured":"Karimaa M, Riikonen R, Kettunen H, Taavitsainen P, Ramela M, Chrusciel M, Karlsson S, Rummakko P, Simola O, Wohlfahrt G, Hakulinen P, Vuorela A, Joensuu H, Utriainen T, Fizazi K, Oksala R (2022) First-in-class small molecule to inhibit CYP11A1 and steroid hormone biosynthesis. Mol Cancer Ther 21:1765\u20131776","journal-title":"Mol Cancer Ther"},{"key":"282_CR270","doi-asserted-by":"crossref","unstructured":"Kaur P, Shankar E, Gupta S (2024) EZH2-mediated development of therapeutic resistance in cancer Cancer. Lett 586:216706","DOI":"10.1016\/j.canlet.2024.216706"},{"key":"282_CR126","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB et al (2024) Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study. Cancer Discov 14:76\u201389","journal-title":"Cancer Discov"},{"key":"282_CR127","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1158\/1078-0432.CCR-20-4968","volume":"27","author":"DH Kim","year":"2021","unstructured":"Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES et al (2021) BET bromodomain inhibition blocks an AR-repressed, E2F1-activated treatment-emergent neuroendocrine prostate cancer lineage plasticity program. Clin Cancer Res 27:4923\u20134936","journal-title":"Clin Cancer Res"},{"key":"282_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45489-4","volume":"15","author":"WK Kim","year":"2024","unstructured":"Kim WK, Buckley AJ, Lee DH, Hiroto A, Nenninger CH, Olson AW, Wang J, Li Z, Vikram R, Adzavon YM, Yau TY, Bao Y, Kahn M, Geradts J, Xiao GQ, Sun Z (2024) Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation. Nat Commun 15:1231","journal-title":"Nat Commun"},{"key":"282_CR129","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED (2011) Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pr 65:1180\u20131192","journal-title":"Int J Clin Pr"},{"key":"282_CR130","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/jama.2011.1437","volume":"306","author":"EA Klein","year":"2011","unstructured":"Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM et al (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306:1549\u20131556","journal-title":"JAMA"},{"key":"282_CR131","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature12750","volume":"502","author":"RM Kohli","year":"2013","unstructured":"Kohli RM, Zhang Y (2013) TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502:472\u2013479","journal-title":"Nature"},{"key":"282_CR132","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/biom12020309","volume":"12","author":"S Koushyar","year":"2022","unstructured":"Koushyar S, Meniel VS, Phesse TJ, Pearson HB (2022) Exploring the Wnt pathway as a therapeutic target for prostate cancer. Biomolecules 12:309","journal-title":"Biomolecules"},{"key":"282_CR133","doi-asserted-by":"publisher","first-page":"26259","DOI":"10.18632\/oncotarget.8456","volume":"7","author":"S Kregel","year":"2016","unstructured":"Kregel S, Chen JL, Tom W, Krishnan V, Kach J, Brechka H, Fessenden TB, Isikbay M, Paner GP, Szmulewitz RZ, Vander Griend DJ (2016) Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget 7:26259\u201326274","journal-title":"Oncotarget"},{"key":"282_CR134","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","volume":"16","author":"SY Ku","year":"2019","unstructured":"Ku SY, Gleave ME, Beltran H (2019) Towards precision oncology in advanced prostate cancer. Nat Rev Urol 16:645\u2013654","journal-title":"Nat Rev Urol"},{"key":"282_CR135","doi-asserted-by":"publisher","first-page":"e167440","DOI":"10.1172\/jci.insight.167440","volume":"8","author":"A Kumaraswamy","year":"2023","unstructured":"Kumaraswamy A, Duan Z, Flores D, Zhang C, Sehrawat A, Hu YM, Swaim OA, Rodansky E, Storck WK, Kuleape JA et al (2023) LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function. JCI Insight 8:e167440","journal-title":"JCI Insight"},{"key":"282_CR136","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A et al (2019) Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest 129:4492\u20134505","journal-title":"J Clin Invest"},{"key":"282_CR137","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1158\/1535-7163.MCT-17-1138","volume":"17","author":"W Leconet","year":"2018","unstructured":"Leconet W, Liu H, Guo M, Le Lamer-Dechamps S, Molinier C, Kim S, Vrlinic T, Oster M, Liu F, Navarro V, Batra JS, Noriega AL, Grizot S, Bander NH (2018) Anti-PSMA\/CD3 bispecific antibody delivery and antitumor activity using a polymeric depot formulation. Mol Cancer Ther 17:1927\u20131940","journal-title":"Mol Cancer Ther"},{"key":"282_CR138","doi-asserted-by":"publisher","first-page":"E4473","DOI":"10.1073\/pnas.1802354115","volume":"115","author":"JK Lee","year":"2018","unstructured":"Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci USA 115:E4473\u2013E4482","journal-title":"Proc Natl Acad Sci USA"},{"key":"282_CR139","doi-asserted-by":"publisher","first-page":"eabb9601","DOI":"10.1126\/science.abb9601","volume":"369","author":"AM Lennon","year":"2020","unstructured":"Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, Ledbetter DH, Sanfilippo F, Sheridan K, Rosica D et al (2020) Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 369:eabb9601","journal-title":"Science"},{"key":"282_CR140","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41422-024-01025-z","volume":"35","author":"F Li","year":"2025","unstructured":"Li F, Dai P, Shi H, Zhang Y, He J, Gopalan A, Li D, Chen Y, Du Y, Xu G, Yang W, Liang C, Gao D (2025) LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer. Cell Res 35:59\u201371","journal-title":"Cell Res"},{"key":"282_CR141","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J (2020) PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 19:107","journal-title":"Mol Cancer"},{"key":"282_CR142","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41374-019-0343-5","volume":"100","author":"H Li","year":"2020","unstructured":"Li H, Wang L, Li Z, Geng X, Li M, Tang Q, Wu C, Lu Z (2020) SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer. Lab Invest 100:570\u2013582","journal-title":"Lab Invest"},{"key":"282_CR143","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1158\/0008-5472.CAN-22-2433","volume":"83","author":"M Li","year":"2023","unstructured":"Li M, Liu M, Han W, Wang Z, Han D, Patalano S, Macoska JA, Balk SP, He HH, Corey E, Gao S, Cai C (2023) LSD1 inhibition disrupts super-enhancer-driven oncogenic transcriptional programs in castration-resistant prostate cancer. Cancer Res 83:1684\u20131698","journal-title":"Cancer Res"},{"key":"282_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34871-9","volume":"13","author":"N Li","year":"2022","unstructured":"Li N, Liu Q, Han Y, Pei S, Cheng B, Xu J, Miao X, Pan Q, Wang H, Guo J et al (2022) ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat Commun 13:7281","journal-title":"Nat Commun"},{"key":"282_CR145","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","volume":"73","author":"Y Li","year":"2013","unstructured":"Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73:483\u2013489","journal-title":"Cancer Res"},{"key":"282_CR146","doi-asserted-by":"publisher","first-page":"843604","DOI":"10.3389\/fcell.2022.843604","volume":"10","author":"Y Liao","year":"2022","unstructured":"Liao Y, Wu M, Jia Y, Mou R, Li X (2022) EpCAM as a novel biomarker for survivals in prostate cancer patients. Front Cell Dev Biol 10:843604","journal-title":"Front Cell Dev Biol"},{"key":"282_CR147","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells?. Trends Biochem Sci 41:211\u2013218","journal-title":"Trends Biochem Sci"},{"key":"282_CR148","first-page":"3550","volume":"61","author":"MJ Linja","year":"2001","unstructured":"Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550\u20133555","journal-title":"Cancer Res"},{"key":"282_CR149","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.3390\/cancers12113339","volume":"12","author":"MA Lounis","year":"2020","unstructured":"Lounis MA, Peant B, Leclerc-Desaulniers K, Ganguli D, Daneault C, Ruiz M, Zoubeidi A, Mes-Masson AM, Saad F (2020) Modulation of de novo lipogenesis improves response to enzalutamide treatment in prostate cancer. Cancers 12:3339","journal-title":"Cancers"},{"key":"282_CR150","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","volume":"19","author":"F Lyko","year":"2018","unstructured":"Lyko F (2018) The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet 19:81\u201392","journal-title":"Nat Rev Genet"},{"key":"282_CR151","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ajur.2019.12.003","volume":"7","author":"CY Mah","year":"2020","unstructured":"Mah CY, Nassar ZD, Swinnen JV, Butler LM (2020) Lipogenic effects of androgen signaling in normal and malignant prostate. Asian J Urol 7:258\u2013270","journal-title":"Asian J Urol"},{"key":"282_CR152","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1158\/2159-8290.CD-20-1114","volume":"11","author":"AC Mandigo","year":"2021","unstructured":"Mandigo AC, Yuan W, Xu K, Gallagher P, Pang A, Guan YF, Shafi AA, Thangavel C, Sheehan B, Bogdan D et al (2021) RB\/E2F1 as a master regulator of cancer cell metabolism in advanced disease. Cancer Discov 11:2334\u20132353","journal-title":"Cancer Discov"},{"key":"282_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00214-y","volume":"5","author":"AS Mansfield","year":"2021","unstructured":"Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R (2021) A phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol 5:74","journal-title":"NPJ Precis Oncol"},{"key":"282_CR154","doi-asserted-by":"crossref","unstructured":"Mansinho AMD, Fernandes I, Costa L (2018) Castration-resistant prostate cancer: mechanisms, targets and treatment. Springer, Cham","DOI":"10.1007\/978-3-319-99286-0_7"},{"key":"282_CR155","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.3390\/cancers13194960","volume":"13","author":"M Marin-Aguilera","year":"2021","unstructured":"Marin-Aguilera M, Pereira MV, Jimenez N, Reig O, Cuartero A, Victoria I, Aversa C, Ferrer-Mileo L, Prat A, Mellado B (2021) Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanes. Cancers 13:4960","journal-title":"Cancers"},{"key":"282_CR156","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41391-022-00609-3","volume":"26","author":"F Marino","year":"2023","unstructured":"Marino F, Totaro A, Gandi C, Bientinesi R, Moretto S, Gavi F, Pierconti F, Iacovelli R, Bassi P, Sacco E (2023) Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine. Prostate Cancer Prostatic Dis 26:655\u2013664","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"282_CR157","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2023.41.6_suppl.190","volume":"41","author":"MC Markowski","year":"2023","unstructured":"Markowski MC, Sternberg CN, Wang H, Sullivan R, King S, Lotan TL, Antonarakis ES (2023) TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations. J Clin Oncol 41:190\u2013190","journal-title":"J Clin Oncol"},{"key":"282_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44514-2","volume":"15","author":"MC Markowski","year":"2024","unstructured":"Markowski MC, Taplin ME, Aggarwal R, Sena LA, Wang H, Qi H, Lalji A, Sinibaldi V, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Sanin DE, Yegnasubramanian S, Gomes-Alexandre C, Ozbek B, Jones T, De Marzo AM, Denmeade SR, Antonarakis ES (2024) Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nat Commun 15:14","journal-title":"Nat Commun"},{"key":"282_CR159","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:1697\u20131708","journal-title":"N Engl J Med"},{"key":"282_CR160","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108\u2013112","journal-title":"Nature"},{"key":"282_CR161","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1093\/oncolo\/oyac172","volume":"27","author":"N Mehra","year":"2022","unstructured":"Mehra N, Fizazi K, de Bono JS, Barthelemy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV (2022) Talazoparib, a poly(ADP-ribose) polymerase inhibitor, for metastatic castration-resistant prostate cancer and DNA damage response alterations: TALAPRO-1 safety analyses. Oncologist 27:e783\u2013e795","journal-title":"Oncologist"},{"key":"282_CR162","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","volume":"8","author":"TB Miranda","year":"2009","unstructured":"Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE, Jones PA (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8:1579\u20131588","journal-title":"Mol Cancer Ther"},{"key":"282_CR163","doi-asserted-by":"publisher","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","volume":"14","author":"JL Mohler","year":"2016","unstructured":"Mohler JL, Armstrong AJ, Bahnson RR, D\u2019Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM et al (2016) Prostate cancer, version 1.2016. J Natl Compr Canc Netw 14:19\u201330","journal-title":"J Natl Compr Canc Netw"},{"key":"282_CR164","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10637-018-0630-9","volume":"36","author":"P Monk","year":"2018","unstructured":"Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA (2018) Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest N Drugs 36:919\u2013926","journal-title":"Invest N Drugs"},{"key":"282_CR165","doi-asserted-by":"crossref","unstructured":"Moore GL, Zeng VG, Diaz JE, Bonzon C, Avery KN, Rashid R, Qi J, Nam DH, Jacinto J, Dragovich MA, Kim YK, Balcazar KP, Bakhit CG, Eivazi A, Nguyen H, Muchhal US, Szymkowski DE, Desjarlais JR, Hedvat M (2025) A B7-H3-targeted CD28 bispecific antibody enhances the activity of anti-PD1 and CD3 T-cell engager immunotherapies. Mol Cancer Ther 24:331\u2013344","DOI":"10.1158\/1535-7163.MCT-24-0327"},{"key":"282_CR166","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495\u20132505","journal-title":"N Engl J Med"},{"key":"282_CR167","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s43018-021-00185-w","volume":"2","author":"KL Morel","year":"2021","unstructured":"Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, Qiu X, Canadas I, Roehle K, Heckler M et al (2021) EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer 2:444\u2013456","journal-title":"Nat Cancer"},{"key":"282_CR168","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","volume":"16","author":"MJ Morris","year":"2019","unstructured":"Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, Scholz A, Sgouros G (2019) Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol 16:745\u2013756","journal-title":"Nat Rev Urol"},{"key":"282_CR169","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/s41591-024-03060-0","volume":"30","author":"T Mukohara","year":"2024","unstructured":"Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM et al (2024) Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial. Nat Med 30:2242\u20132250","journal-title":"Nat Med"},{"key":"282_CR170","doi-asserted-by":"publisher","first-page":"110240","DOI":"10.1016\/j.cellsig.2021.110240","volume":"91","author":"S Natani","year":"2022","unstructured":"Natani S, Sruthi KK, Asha SM, Khilar P, Lakshmi PSV, Ummanni R (2022) Activation of TGF-beta - SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK. Cell Signal 91:110240","journal-title":"Cell Signal"},{"key":"282_CR171","doi-asserted-by":"publisher","first-page":"127763","DOI":"10.1016\/j.bmcl.2020.127763","volume":"34","author":"M Naveen Sadhu","year":"2021","unstructured":"Naveen Sadhu M, Sivanandhan D, Gajendran C, Tantry S, Dewang P, Murugan K, Chickamunivenkatappa S, Zainuddin M, Nair S, Vaithilingam K, Rajagopal S (2021) Novel dual LSD1\/HDAC6 inhibitors for the treatment of multiple myeloma. Bioorg Med Chem Lett 34:127763","journal-title":"Bioorg Med Chem Lett"},{"key":"282_CR172","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-24-0400","volume":"30","author":"CB Nguyen","year":"2024","unstructured":"Nguyen CB, Reimers MA, Perera C, Abida W, Chou J, Feng FY, Antonarakis ES, McKay RR, Pachynski RK, Zhang J et al (2024) Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial. Clin Cancer Res 30:3200\u20133210","journal-title":"Clin Cancer Res"},{"key":"282_CR173","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/cancers12030660","volume":"12","author":"K Nikhil","year":"2020","unstructured":"Nikhil K, Raza A, Haymour HS, Flueckiger BV, Chu J, Shah K (2020) Aurora kinase A-YBX1 synergy fuels aggressive oncogenic phenotypes and chemoresistance in castration-resistant prostate cancer. Cancers 12:660","journal-title":"Cancers"},{"key":"282_CR174","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1001\/jamaoncol.2025.1059","volume":"11","author":"J Nikitas","year":"2025","unstructured":"Nikitas J, Ballas LK, Romero T, Lynch C, Ma TM, Valle LF, Sachdeva A, Chong N, Basehart V, Franco A et al (2025) Patient-reported outcomes with stereotactic intensity modulated radiotherapy after radical prostatectomy: a nonrandomized clinical trial. JAMA Oncol 11:726\u2013734","journal-title":"JAMA Oncol"},{"key":"282_CR1","doi-asserted-by":"crossref","unstructured":"No authors listed (2023) LBA02-09 EMBARK: a phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. J Urol 210:224\u2013226","DOI":"10.1097\/JU.0000000000003518"},{"key":"282_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29963-5","volume":"13","author":"S Nouruzi","year":"2022","unstructured":"Nouruzi S, Ganguli D, Tabrizian N, Kobelev M, Sivak O, Namekawa T, Thaper D, Baca SC, Freedman ML, Aguda A, Davies A, Zoubeidi A (2022) ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nat Commun 13:2282","journal-title":"Nat Commun"},{"key":"282_CR176","doi-asserted-by":"publisher","first-page":"bqad023","DOI":"10.1210\/endocr\/bqad023","volume":"164","author":"S Nouruzi","year":"2023","unstructured":"Nouruzi S, Tabrizian N, Zoubeidi A (2023) Beyond expression: role of phosphorylated residues of EZH2 in lineage plasticity in prostate cancer. Endocrinology 164:bqad023","journal-title":"Endocrinology"},{"key":"282_CR177","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.21037\/tau-20-1131","volume":"10","author":"K Okasho","year":"2021","unstructured":"Okasho K, Ogawa O, Akamatsu S (2021) Narrative review of challenges in the management of advanced neuroendocrine prostate cancer. Transl Androl Urol 10:3953\u20133962","journal-title":"Transl Androl Urol"},{"key":"282_CR178","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fonc.2019.00396","volume":"9","author":"AF Oliveira","year":"2019","unstructured":"Oliveira AF, Bretes L, Furtado I (2019) Review of PD-1\/PD-L1 inhibitors in metastatic dMMR\/MSI-H colorectal cancer. Front Oncol 9:396","journal-title":"Front Oncol"},{"key":"282_CR179","doi-asserted-by":"publisher","first-page":"e55257","DOI":"10.1371\/journal.pone.0055257","volume":"8","author":"RF Overcash","year":"2013","unstructured":"Overcash RF, Chappell VA, Green T, Geyer CB, Asch AS, Ruiz-Echevarria MJ (2013) Androgen signaling promotes translation of TMEFF2 in prostate cancer cells via phosphorylation of the alpha subunit of the translation initiation factor 2. PLoS ONE 8:e55257","journal-title":"PLoS ONE"},{"key":"282_CR180","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/pros.24315","volume":"82","author":"B Ozbek","year":"2022","unstructured":"Ozbek B, Ertunc O, Erickson A, Vidal ID, Gomes-Alexandre C, Guner G, Hicks JL, Jones T, Taube JM, Sfanos KS, Yegnasubramanian S, De Marzo AM (2022) Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer. Prostate 82:706\u2013722","journal-title":"Prostate"},{"key":"282_CR181","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-21-0024","volume":"27","author":"PL Palmbos","year":"2021","unstructured":"Palmbos PL, Daignault-Newton S, Tomlins SA, Agarwal N, Twardowski P, Morgans AK, Kelly WK, Arora VK, Antonarakis ES, Siddiqui J, Jacobson JA, Davenport MS, Robinson DR, Chinnaiyan AM, Knudsen KE, Hussain M (2021) A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone-sensitive prostate cancer. Clin Cancer Res 27:3017\u20133027","journal-title":"Clin Cancer Res"},{"key":"282_CR182","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.bbrc.2014.11.105","volume":"456","author":"T Pan","year":"2015","unstructured":"Pan T, Gao L, Wu G, Shen G, Xie S, Wen H, Yang J, Zhou Y, Tu Z, Qian W (2015) Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer. Biochem Biophys Res Commun 456:452\u2013458","journal-title":"Biochem Biophys Res Commun"},{"key":"282_CR183","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.1038\/s41388-021-01982-4","volume":"40","author":"SH Park","year":"2021","unstructured":"Park SH, Fong KW, Mong E, Martin MC, Schiltz GE, Yu J (2021) Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene 40:5788\u20135798","journal-title":"Oncogene"},{"key":"282_CR184","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213\u2013223","journal-title":"N Engl J Med"},{"key":"282_CR185","doi-asserted-by":"publisher","first-page":"104524","DOI":"10.1016\/j.critrevonc.2024.104524","volume":"204","author":"A Peddio","year":"2024","unstructured":"Peddio A, Pietroluongo E, Lamia MR, Luciano A, Caltavituro A, Buonaiuto R, Pecoraro G, De Placido P, Palmieri G, Bianco R, Giuliano M, Servetto A (2024) DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: a narrative review. Crit Rev Oncol Hematol 204:104524","journal-title":"Crit Rev Oncol Hematol"},{"key":"282_CR186","first-page":"CD008871","volume":"6","author":"F Peinemann","year":"2011","unstructured":"Peinemann F, Grouven U, Hemkens LG, Bartel C, Borchers H, Pinkawa M, Heidenreich A, Sauerland S (2011) Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst Rev 6:CD008871","journal-title":"Cochrane Database Syst Rev"},{"key":"282_CR187","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/pros.23765","volume":"79","author":"DP Petrylak","year":"2019","unstructured":"Petrylak DP, Kantoff P, Vogelzang NJ, Mega A, Fleming MT, Stephenson JJ Jr, Frank R, Shore ND, Dreicer R, McClay EF, Berry WR, Agarwal M, DiPippo VA, Rotshteyn Y, Stambler N, Olson WC, Morris SA, Israel RJ (2019) Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. Prostate 79:604\u2013613","journal-title":"Prostate"},{"key":"282_CR188","doi-asserted-by":"publisher","first-page":"100082","DOI":"10.1016\/j.esmoop.2021.100082","volume":"6","author":"DP Petrylak","year":"2021","unstructured":"Petrylak DP, Vaishampayan UN, Patel KR, Higano CS, Albany C, Dawson NA, Mehlhaff BA, Quinn DI, Nordquist LT, Wagner VJ, Siegel J, Trandafir L, Sartor O (2021) A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate\/prednisone or enzalutamide. ESMO Open 6:100082","journal-title":"ESMO Open"},{"key":"282_CR189","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/pros.23922","volume":"80","author":"DP Petrylak","year":"2020","unstructured":"Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST et al (2020) PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and\/or enzalutamide: efficacy and safety in open-label single-arm phase 2 study. Prostate 80:99\u2013108","journal-title":"Prostate"},{"key":"282_CR190","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/COC.0b013e31818b946b","volume":"32","author":"C Pezaro","year":"2009","unstructured":"Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B, Toner GC (2009) An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol 32:338\u2013341","journal-title":"Am J Clin Oncol"},{"key":"282_CR191","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, Buchschacher GL Jr, Alekseev B, Mellado B, Karaszewska B, Doss JF, Rasuo G, Datye A, Mariathasan S, Williams P, Sweeney CJ (2022) Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med 28:144\u2013153","journal-title":"Nat Med"},{"key":"282_CR192","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41416-024-02762-z","volume":"131","author":"M Pujana-Vaquerizo","year":"2024","unstructured":"Pujana-Vaquerizo M, Bozal-Basterra L, Carracedo A (2024) Metabolic adaptations in prostate cancer. Br J Cancer 131:1250\u20131262","journal-title":"Br J Cancer"},{"key":"282_CR193","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM et al (2018) Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174:758\u2013769.e9","journal-title":"Cell"},{"key":"282_CR194","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nature15529","volume":"527","author":"S Rabinovich","year":"2015","unstructured":"Rabinovich S, Adler L, Yizhak K, Sarver A, Silberman A, Agron S, Stettner N, Sun Q, Brandis A, Helbling D, Korman S, Itzkovitz S, Dimmock D, Ulitsky I, Nagamani SC, Ruppin E, Erez A (2015) Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature 527:379\u2013383","journal-title":"Nature"},{"key":"282_CR195","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"LE Raez","year":"2013","unstructured":"Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ (2013) A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharm 71:523\u2013530","journal-title":"Cancer Chemother Pharm"},{"key":"282_CR196","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2967\/jnumed.122.264456","volume":"64","author":"K Rahbar","year":"2023","unstructured":"Rahbar K, Essler M, Pabst KM, Eiber M, Fougere C, Prasad V, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Fendler WP, Kurtinecz M, Schmall A, Verholen F, Sartor O (2023) Safety and survival outcomes of (177)Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer with prior (223)Ra treatment: the RALU study. J Nucl Med 64:574\u2013578","journal-title":"J Nucl Med"},{"key":"282_CR197","doi-asserted-by":"publisher","unstructured":"Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT (2025) Association of prior PARP inhibitor exposure with clinical outcomes after (177)Lu-PSMA-617 in men with castration-resistant prostate cancer and mutations in DNA homologous recombination repair genes. Eur Urol Oncol https:\/\/doi.org\/10.1016\/j.euo.2025.01.002","DOI":"10.1016\/j.euo.2025.01.002"},{"key":"282_CR198","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.01.018","volume":"35","author":"M Reina-Campos","year":"2019","unstructured":"Reina-Campos M, Linares JF, Duran A, Cordes T, L\u2019Hermitte A, Badur MG, Bhangoo MS, Thorson PK, Richards A, Rooslid T, Garcia-Olmo DC, Nam-Cha SY, Salinas-Sanchez AS, Eng K, Beltran H, Scott DA, Metallo CM, Moscat J, Diaz-Meco MT (2019) Increased serine and one-carbon pathway metabolism by PKClambda\/iota deficiency promotes neuroendocrine prostate cancer. Cancer Cell 35:385\u2013400.e9","journal-title":"Cancer Cell"},{"key":"282_CR199","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355","journal-title":"Science"},{"key":"282_CR200","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G et al (2015a) Integrative clinical genomics of advanced prostate cancer. Cell 162:454","journal-title":"Cell"},{"key":"282_CR201","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G et al (2015b) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215\u20131228","journal-title":"Cell"},{"key":"282_CR202","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091\u20131103","journal-title":"N Engl J Med"},{"key":"282_CR203","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2017-0413","volume":"23","author":"O Sartor","year":"2018","unstructured":"Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ, Investigators USEAP (2018) Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. Experience from an Expanded Access Program. Oncologist 23:193\u2013202","journal-title":"Oncologist"},{"key":"282_CR204","doi-asserted-by":"publisher","first-page":"e162907","DOI":"10.1172\/jci.insight.162907","volume":"8","author":"E Sayar","year":"2023","unstructured":"Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V et al (2023) Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight 8:e162907","journal-title":"JCI Insight"},{"key":"282_CR205","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","volume":"42","author":"G Seed","year":"2024","unstructured":"Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, Tyler M, Figueiredo I, Pereira R, Baker C et al (2024) Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell 42:2113\u20132123.e4","journal-title":"Cancer Cell"},{"key":"282_CR206","doi-asserted-by":"publisher","first-page":"e162396","DOI":"10.1172\/JCI162396","volume":"132","author":"LA Sena","year":"2022","unstructured":"Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL et al (2022) Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC. J Clin Invest 132:e162396","journal-title":"J Clin Invest"},{"key":"282_CR207","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ejca.2020.11.043","volume":"144","author":"LA Sena","year":"2021","unstructured":"Sena LA, Wang H, Lim Sc MS, Rifkind I, Ngomba N, Isaacs JT, Luo J, Pratz C, Sinibaldi V, Carducci MA, Paller CJ, Eisenberger MA, Markowski MC, Antonarakis ES, Denmeade SR (2021) Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. Eur J Cancer 144:302\u2013309","journal-title":"Eur J Cancer"},{"key":"282_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46666-1","volume":"15","author":"F Serra","year":"2024","unstructured":"Serra F, Nieto-Aliseda A, Fanlo-Escudero L, Rovirosa L, Cabrera-Pasadas M, Lazarenkov A, Urmeneta B, Alcalde-Merino A, Nola EM, Okorokov AL, Fraser P, Graupera M, Castillo SD, Sardina JL, Valencia A, Javierre BM (2024) p53 rapidly restructures 3D chromatin organization to trigger a transcriptional response. Nat Commun 15:2821","journal-title":"Nat Commun"},{"key":"282_CR209","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41391-020-0246-y","volume":"24","author":"JS Shafran","year":"2021","unstructured":"Shafran JS, Jafari N, Casey AN, Gyorffy B, Denis GV (2021) BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 24:268\u2013277","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"282_CR210","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cpt.2022.12.003","volume":"1","author":"B Shree","year":"2023","unstructured":"Shree B, Das K, Sharma V (2023) Emerging role of transforming growth factor-beta-regulated long non-coding RNAs in prostate cancer pathogenesis. Cancer Pathog Ther 1:195\u2013204","journal-title":"Cancer Pathog Ther"},{"key":"282_CR211","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1464-410X.2007.07121.x","volume":"100","author":"EJ Small","year":"2007","unstructured":"Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF (2007) A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 100:765\u2013769","journal-title":"BJU Int"},{"key":"282_CR212","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","volume":"23","author":"MR Smith","year":"2022","unstructured":"Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Stahl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K, investigators G (2022) Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol 23:362\u2013373","journal-title":"Lancet Oncol"},{"key":"282_CR213","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1158\/1078-0432.CCR-22-1305","volume":"29","author":"JM Sperger","year":"2023","unstructured":"Sperger JM, Helzer KT, Stahlfeld CN, Jiang D, Singh A, Kaufmann KR, Niles DJ, Heninger E, Rydzewski NR, Wang L et al (2023) Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer. Clin Cancer Res 29:2324\u20132335","journal-title":"Clin Cancer Res"},{"key":"282_CR214","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/pros.21172","volume":"70","author":"M Stein","year":"2010","unstructured":"Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, Eddy S, Goodin S, White E, Dipaola RS (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70:1388\u20131394","journal-title":"Prostate"},{"key":"282_CR215","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M, Investigators P (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382:2197\u20132206","journal-title":"N Engl J Med"},{"key":"282_CR216","doi-asserted-by":"publisher","first-page":"e005813","DOI":"10.1136\/jitc-2022-005813","volume":"11","author":"J Strauss","year":"2023","unstructured":"Strauss J, Deville JL, Sznol M, Ravaud A, Maruzzo M, Pachynski RK, Gourdin TS, Maio M, Dirix L, Schlom J, Donahue RN, Tsai YT, Wang X, Vugmeyster Y, Beier F, Seebeck J, Schroeder A, Chennoufi S, Gulley JL (2023) First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. J Immunother Cancer 11:e005813","journal-title":"J Immunother Cancer"},{"key":"282_CR217","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.bbcan.2019.01.001","volume":"1871","author":"V Strmiska","year":"2019","unstructured":"Strmiska V, Michalek P, Eckschlager T, Stiborova M, Adam V, Krizkova S, Heger Z (2019) Prostate cancer-specific hallmarks of amino acids metabolism: towards a paradigm of precision medicine. Biochim Biophys Acta Rev Cancer 1871:248\u2013258","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"282_CR218","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz J, Fong L (2021) How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis 24:697\u2013717","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"282_CR219","first-page":"187","volume":"18","author":"Q Sun","year":"2019","unstructured":"Sun Q, Hu LL, Fu Q (2019) MCT4 promotes cell proliferation and invasion of castration-resistant prostate cancer PC-3 cell line. EXCLI J 18:187\u2013194","journal-title":"EXCLI J"},{"key":"282_CR220","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-22-2228","volume":"28","author":"U Swami","year":"2022","unstructured":"Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N (2022a) SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer. Clin Cancer Res 28:4917\u20134925","journal-title":"Clin Cancer Res"},{"key":"282_CR221","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-22-2228","volume":"28","author":"U Swami","year":"2022","unstructured":"Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, Agarwal N (2022b) SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer. Clin Cancer Res 28:4917\u20134925","journal-title":"Clin Cancer Res"},{"key":"282_CR222","doi-asserted-by":"publisher","first-page":"eadk9167","DOI":"10.1126\/science.adk9167","volume":"386","author":"MM Swamynathan","year":"2024","unstructured":"Swamynathan MM, Kuang S, Watrud KE, Doherty MR, Gineste C, Mathew G, Gong GQ, Cox H, Cheng E, Reiss D et al (2024) Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function. Science 386:eadk9167","journal-title":"Science"},{"key":"282_CR223","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis F (2021) Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398:131\u2013142","journal-title":"Lancet"},{"key":"282_CR224","first-page":"1086","volume":"57","author":"JV Swinnen","year":"1997","unstructured":"Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G (1997) Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 57:1086\u20131090","journal-title":"Cancer Res"},{"key":"282_CR225","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/1541-7786.MCR-23-0976","volume":"22","author":"ZE Sychev","year":"2024","unstructured":"Sychev ZE, Day A, Bergom HE, Larson G, Ali A, Ludwig M, Boytim E, Coleman I, Corey E, Plymate SR, Nelson PS, Hwang JH, Drake JM (2024) Unraveling the global proteome and phosphoproteome of prostate cancer patient-derived xenografts. Mol Cancer Res 22:452\u2013464","journal-title":"Mol Cancer Res"},{"key":"282_CR226","doi-asserted-by":"publisher","first-page":"112937","DOI":"10.1016\/j.celrep.2023.112937","volume":"42","author":"N Tabrizian","year":"2023","unstructured":"Tabrizian N, Nouruzi S, Cui CJ, Kobelev M, Namekawa T, Lodhia I, Talal A, Sivak O, Ganguli D, Zoubeidi A (2023) ASCL1 is activated downstream of the ROR2\/CREB signaling pathway to support lineage plasticity in prostate cancer. Cell Rep 42:112937","journal-title":"Cell Rep"},{"key":"282_CR227","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-021-01061-x","volume":"14","author":"D Teyssonneau","year":"2021","unstructured":"Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong NS, Soubeyran I, Sevenet N, Roubaud G (2021) Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol 14:51","journal-title":"J Hematol Oncol"},{"key":"282_CR228","first-page":"318","volume":"9","author":"B Thompson-Elliott","year":"2021","unstructured":"Thompson-Elliott B, Johnson R, Khan SA (2021) Alterations in TGFbeta signaling during prostate cancer progression. Am J Clin Exp Urol 9:318\u2013328","journal-title":"Am J Clin Exp Urol"},{"key":"282_CR229","doi-asserted-by":"publisher","first-page":"101758","DOI":"10.1016\/j.xcrm.2024.101758","volume":"5","author":"JC Tien","year":"2024","unstructured":"Tien JC, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, Yang J, Mannan R, Mahapatra S, Shah P et al (2024) CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell Rep Med 5:101758","journal-title":"Cell Rep Med"},{"key":"282_CR230","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/1078-0432.CCR-14-2610","volume":"21","author":"BK Tomlinson","year":"2015","unstructured":"Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN Jr (2015) Phase I trial of arginine deprivation therapy with ADI-PEG 20 Plus docetaxel in patients with advanced malignant solid tumors. Clin Cancer Res 21:2480\u20132486","journal-title":"Clin Cancer Res"},{"key":"282_CR231","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3892\/ijo.2014.2601","volume":"45","author":"P Toren","year":"2014","unstructured":"Toren P, Zoubeidi A (2014) Targeting the PI3K\/Akt pathway in prostate cancer: challenges and opportunities (review). Int J Oncol 45:1793\u20131801","journal-title":"Int J Oncol"},{"key":"282_CR232","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/ajcn\/nqz012","volume":"109","author":"MH Traka","year":"2019","unstructured":"Traka MH, Melchini A, Coode-Bate J, Al Kadhi O, Saha S, Defernez M, Troncoso-Rey P, Kibblewhite H, O\u2019Neill CM, Bernuzzi F, Mythen L, Hughes J, Needs PW, Dainty JR, Savva GM, Mills RD, Ball RY, Cooper CS, Mithen RF (2019) Transcriptional changes in prostate of men on active surveillance after a 12-mo glucoraphanin-rich broccoli intervention-results from the Effect of Sulforaphane on prostate CAncer PrEvention (ESCAPE) randomized controlled trial. Am J Clin Nutr 109:1133\u20131144","journal-title":"Am J Clin Nutr"},{"key":"282_CR233","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35880-y","volume":"14","author":"T Tsujino","year":"2023","unstructured":"Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z et al (2023) CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun 14:252","journal-title":"Nat Commun"},{"key":"282_CR234","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1158\/1535-7163.MCT-23-0540","volume":"23","author":"T Uo","year":"2024","unstructured":"Uo T, Ojo KK, Sprenger CCT, Epilepsia KS, Perera BGK, Damodarasamy M, Sun S, Kim S, Hogan HH, Hulverson MA et al (2024) A compound that inhibits glycolysis in prostate cancer controls growth of advanced prostate cancer. Mol Cancer Ther 23:973\u2013994","journal-title":"Mol Cancer Ther"},{"key":"282_CR235","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S et al (2024) Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med 391:1413\u20131425","journal-title":"N Engl J Med"},{"key":"282_CR236","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20493-6","volume":"12","author":"G Vandekerkhove","year":"2021","unstructured":"Vandekerkhove G, Lavoie JM, Annala M, Murtha AJ, Sundahl N, Walz S, Sano T, Taavitsainen S, Ritch E, Fazli L, Hurtado-Coll A, Wang G, Nykter M, Black PC, Todenhofer T, Ost P, Gibb EA, Chi KN, Eigl BJ, Wyatt AW (2021) Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun 12:184","journal-title":"Nat Commun"},{"key":"282_CR237","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4161\/cc.6.6.4028","volume":"6","author":"DJ Vander Griend","year":"2007","unstructured":"Vander Griend DJ, Litvinov IV, Isaacs JT (2007) Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 6:647\u2013651","journal-title":"Cell Cycle"},{"key":"282_CR238","doi-asserted-by":"publisher","first-page":"e2416882121","DOI":"10.1073\/pnas.2416882121","volume":"121","author":"G Varuzhanyan","year":"2024","unstructured":"Varuzhanyan G, Chen CC, Freeland J, He T, Tran W, Song K, Wang L, Cheng D, Xu S, Dibernardo GA et al (2024) PGC-1alpha drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. Proc Natl Acad Sci USA 121:e2416882121","journal-title":"Proc Natl Acad Sci USA"},{"key":"282_CR239","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1021\/acs.jmedchem.4c02535","volume":"68","author":"RG Vaswani","year":"2025","unstructured":"Vaswani RG, Huang DS, Anthony N, Xu L, Centore R, Schiller S, Li Z, Fan H, Setser J, Zawadzke LE et al (2025) Discovery of FHD-286, a first-in-class, orally bioavailable, allosteric dual inhibitor of the Brahma homologue (BRM) and Brahma-related gene 1 (BRG1) ATPase activity for the treatment of switch\/sucrose non-fermentable (SWI\/SNF) dependent cancers. J Med Chem 68:1772\u20131792","journal-title":"J Med Chem"},{"key":"282_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51156-5","volume":"15","author":"VB Venkadakrishnan","year":"2024","unstructured":"Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, Voss NCE, Mahadevan NR, Mizuno K, Puca L, Idahor O, Ku SY, Bakht MK, Borah AA, Herbert ZT, Tolstorukov MY, Barbie DA, Rickman DS, Brown M, Beltran H (2024) Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat Commun 15:6779","journal-title":"Nat Commun"},{"key":"282_CR241","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1021\/ml3003346","volume":"3","author":"SK Verma","year":"2012","unstructured":"Verma SK, Tian X, LaFrance LV, Duquenne C, Suarez DP, Newlander KA, Romeril SP, Burgess JL, Grant SW, Brackley JA et al (2012) Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett 3:1091\u20131096","journal-title":"ACS Med Chem Lett"},{"key":"282_CR242","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","volume":"174","author":"SR Viswanathan","year":"2018","unstructured":"Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J et al (2018) Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell 174:433\u2013447.e19","journal-title":"Cell"},{"key":"282_CR243","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-017-0593-6","volume":"19","author":"PJ Vlachostergios","year":"2017","unstructured":"Vlachostergios PJ, Puca L, Beltran H (2017) Emerging variants of castration-resistant prostate cancer. Curr Oncol Rep 19:32","journal-title":"Curr Oncol Rep"},{"key":"282_CR244","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2020.05.007","volume":"485","author":"J Wang","year":"2020","unstructured":"Wang J, Xu W, Wang B, Lin G, Wei Y, Abudurexiti M, Zhu W, Liu C, Qin X, Dai B, Wan F, Zhang H, Zhu Y, Ye D (2020) GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett 485:45\u201355","journal-title":"Cancer Lett"},{"key":"282_CR245","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1530\/ERC-17-0051","volume":"25","author":"MA White","year":"2018","unstructured":"White MA, Tsouko E, Lin C, Rajapakshe K, Spencer JM, Wilkenfeld SR, Vakili SS, Pulliam TL, Awad D, Nikolos F, Katreddy RR, Kaipparettu BA, Sreekumar A, Zhang X, Cheung E, Coarfa C, Frigo DE (2018) GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. Endocr Relat Cancer 25:453\u2013469","journal-title":"Endocr Relat Cancer"},{"key":"282_CR246","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Bjornlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellen E, Franzen L, Nilsson P (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385\u2013395","journal-title":"Lancet"},{"key":"282_CR247","first-page":"46","volume":"35","author":"CH Wong","year":"2025","unstructured":"Wong CH, Nicoletti R, Mazzone E, Eapen RS (2025) Lutetium-177-prostate-specific membrane antigen therapy for prostate cancer: current status and future prospects. Curr Opin Urol 35:46\u201352","journal-title":"Curr Opin Urol"},{"key":"282_CR248","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1074\/jbc.M608487200","volume":"282","author":"C Wu","year":"2007","unstructured":"Wu C, Huang J (2007) Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282:3571\u20133583","journal-title":"J Biol Chem"},{"key":"282_CR249","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/1535-7163.MCT-20-0848","volume":"20","author":"C Wu","year":"2021","unstructured":"Wu C, Peng S, Pilie PG, Geng C, Park S, Manyam GC, Lu Y, Yang G, Tang Z, Kondraganti S, Wang D, Hudgens CW, Ledesma DA, Marques-Piubelli ML, Torres-Cabala CA, Curry JL, Troncoso P, Corn PG, Broom BM, Thompson TC (2021) PARP and CDK4\/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer. Mol Cancer Ther 20:1680\u20131691","journal-title":"Mol Cancer Ther"},{"key":"282_CR250","doi-asserted-by":"publisher","first-page":"188842","DOI":"10.1016\/j.bbcan.2022.188842","volume":"1878","author":"W Wu","year":"2023","unstructured":"Wu W, Yu S, Yu X (2023) Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy. Biochim Biophys Acta Rev Cancer 1878:188842","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"282_CR251","first-page":"111","volume":"2","author":"X Wu","year":"2014","unstructured":"Wu X, Daniels G, Lee P, Monaco ME (2014) Lipid metabolism in prostate cancer. Am J Clin Exp Urol 2:111\u2013120","journal-title":"Am J Clin Exp Urol"},{"key":"282_CR252","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","volume":"173","author":"YM Wu","year":"2018","unstructured":"Wu YM, Cieslik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N et al (2018) Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173:1770\u20131782.e14","journal-title":"Cell"},{"key":"282_CR253","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.18632\/oncotarget.1572","volume":"4","author":"A Wyce","year":"2013","unstructured":"Wyce A, Degenhardt Y, Bai Y, Le B, Korenchuk S, Crouthame MC, McHugh CF, Vessella R, Creasy CL, Tummino PJ, Barbash O (2013) Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 4:2419\u20132429","journal-title":"Oncotarget"},{"key":"282_CR254","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3390\/biom11081188","volume":"11","author":"MA Xavier","year":"2021","unstructured":"Xavier MA, Rezende F, Titze-de-Almeida R, Cornelissen B (2021) BRCAness as a biomarker of susceptibility to PARP inhibitors in glioblastoma multiforme. Biomolecules 11:1188","journal-title":"Biomolecules"},{"key":"282_CR255","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1021\/acsmedchemlett.8b00003","volume":"9","author":"Q Xiang","year":"2018","unstructured":"Xiang Q, Zhang Y, Li J, Xue X, Wang C, Song M, Zhang C, Wang R, Li C, Wu C, Zhou Y, Yang X, Li G, Ding K, Xu Y (2018) Y08060: a selective BET inhibitor for treatment of prostate cancer. ACS Med Chem Lett 9:262\u2013267","journal-title":"ACS Med Chem Lett"},{"key":"282_CR256","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","volume":"601","author":"L Xiao","year":"2022","unstructured":"Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, Carson SE, Chang Y, Wang X, Zhang Y et al (2022) Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer. Nature 601:434\u2013439","journal-title":"Nature"},{"key":"282_CR257","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-17-0483","volume":"23","author":"C Xu","year":"2017","unstructured":"Xu C, Zhang Y, Rolfe PA, Hernandez VM, Guzman W, Kradjian G, Marelli B, Qin G, Qi J, Wang H, Yu H, Tighe R, Lo KM, English JM, Radvanyi L, Lan Y (2017) Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models. Clin Cancer Res 23:5869\u20135880","journal-title":"Clin Cancer Res"},{"key":"282_CR258","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/2159-8290.CD-23-0539","volume":"14","author":"Y Xu","year":"2024","unstructured":"Xu Y, Yang Y, Wang Z, Sjostrom M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J et al (2024) ZNF397 deficiency triggers TET2-driven lineage plasticity and AR-targeted therapy resistance in prostate cancer. Cancer Discov 14:1496\u20131521","journal-title":"Cancer Discov"},{"key":"282_CR259","doi-asserted-by":"publisher","first-page":"eadf6732","DOI":"10.1126\/scitranslmed.adf6732","volume":"15","author":"Y Yamada","year":"2023","unstructured":"Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku SY, Garcia MM, Beltran H (2023) Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci Transl Med 15:eadf6732","journal-title":"Sci Transl Med"},{"key":"282_CR260","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","volume":"25","author":"TA Yap","year":"2019","unstructured":"Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, Stern M, Pene Dumitrescu T, Wang X, Frey S, Carver J, Horner T, Oh C, Khaled A, Dhar A, Johnson PWM (2019) Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors. Clin Cancer Res 25:7331\u20137339","journal-title":"Clin Cancer Res"},{"key":"282_CR261","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.euo.2018.09.014","volume":"2","author":"JC Zarif","year":"2019","unstructured":"Zarif JC, Baena-Del Valle JA, Hicks JL, Heaphy CM, Vidal I, Luo J, Lotan TL, Hooper JE, Isaacs WB, Pienta KJ, De Marzo AM (2019) Mannose receptor-positive macrophage infiltration correlates with prostate cancer onset and metastatic castration-resistant disease. Eur Urol Oncol 2:429\u2013436","journal-title":"Eur Urol Oncol"},{"key":"282_CR262","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1002\/mco2.446","volume":"4","author":"N Zhang","year":"2023","unstructured":"Zhang N, Li Y (2023) Receptor tyrosine kinases: biological functions and anticancer targeted therapy. MedComm 4:e446","journal-title":"MedComm"},{"key":"282_CR263","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm.4379","volume":"23","author":"P Zhang","year":"2017","unstructured":"Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y et al (2017) Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med 23:1055\u20131062","journal-title":"Nat Med"},{"key":"282_CR264","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0796-y","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, Zeng Z, Xiong W (2018) Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer 17:45","journal-title":"Mol Cancer"},{"key":"282_CR274","doi-asserted-by":"crossref","unstructured":"Zhang X, Yang Y, Zou H, Yang Y, Zheng X, Corey E, Zoubeidi A, Mitsiades N, Yu A, Li Y, Chen H (2025) Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors. Acta Pharm Sin B 15:1415\u20131429","DOI":"10.1016\/j.apsb.2025.01.007"},{"key":"282_CR265","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1158\/1078-0432.CCR-21-3858","volume":"28","author":"N Zhao","year":"2022","unstructured":"Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK et al (2022) CUB domain-containing protein 1 (CDCP1) is a target for radioligand therapy in castration-resistant prostate cancer, including PSMA null disease. Clin Cancer Res 28:3066\u20133075","journal-title":"Clin Cancer Res"},{"key":"282_CR266","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12672-024-01074-1","volume":"15","author":"H Zhou","year":"2024","unstructured":"Zhou H, Sun D, Song S, Niu Y, Zhang Y, Lan H, Cui J, Liu H, Liu N, Hou H (2024) Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study. Discov Oncol 15:213","journal-title":"Discov Oncol"},{"key":"282_CR267","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00294-9","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou S, Liu M, Ren F, Meng X, Yu J (2021) The landscape of bispecific T cell engager in cancer treatment. Biomark Res 9:38","journal-title":"Biomark Res"},{"key":"282_CR268","doi-asserted-by":"publisher","first-page":"109210","DOI":"10.1016\/j.biopha.2019.109210","volume":"118","author":"S Zou","year":"2019","unstructured":"Zou S, Wang X, Liu P, Ke C, Xu S (2019) Arginine metabolism and deprivation in cancer therapy. Biomed Pharmacother 118:109210","journal-title":"Biomed Pharmacother"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-025-00282-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:46:49Z","timestamp":1779065209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-025-00282-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":272,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,11]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1038\/s44321-025-00282-8","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Martin Gleave is on the editorial advisory board. This has no bearing on the editorial consideration of this article for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}